By Ethan Covey
Early post-marketing findings suggest that the safety profiles of the two FDA-approved respiratory syncytial virus (RSV) vaccines are consistent with vaccine safety data seen in clinical trials among adults 60 years of age and older. This includes a higher-than-expected number of verified cases of Guillain-Barré syndrome (GBS) (MMWR Morb Mortal Wkly Rep 2024;73[21]:489-494).
“CDC has been closely monitoring GBS since it was identified as a potential safety concern in